| Identification | Back Directory | [Name]
1H-Benzimidazole-2-methanol, 6-[5-chloro-2-[[(3R,4R)-3-hydroxy-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-4-fluoro-α-methyl-1-(1-methylethyl)-, (αR)- | [CAS]
2380321-50-4 | [Synonyms]
CDK4/6-IN-5
1H-Benzimidazole-2-methanol, 6-[5-chloro-2-[[(3R,4R)-3-hydroxy-1-(methylsulfonyl)-4-piperidinyl]amino]-4-pyrimidinyl]-4-fluoro-α-methyl-1-(1-methylethyl)-, (αR)-
(3R,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1 R)-1 -hydroxyethyl]-1 -(propan-2-yl)-1 H-benzimidazol-6-yl}pyrimidin-2-yl)amino]-1-(methylsulfonyl)piperidin-3-ol 1 -[(1S,2R,3R,4R,5S)-4-(acetylamino)-2,3-bis(acetyloxy)-6,8-dioxabicyclo[3.2.1 ]oct-1 -yl]-18,18-bis(17- | [Molecular Formula]
C22H28ClFN6O4S | [MOL File]
2380321-50-4.mol | [Molecular Weight]
527.01 |
| Hazard Information | Back Directory | [Uses]
CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with Kis of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively[1]. (from patent WO2019207463A1 example A93). | [References]
[1] Ping Chen, et al. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. WO2019207463A1. |
|
|